Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer
Conditions : Left-sided Colorectal Cancer Interventions : Drug: Petosemtamab; Drug: Cetuximab; Drug: FOLFIRI; Drug: mFOLFOX6 Sponsors : Genmab Not yet recruiting
Read the full article2d agoen
You might also wanna read
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
clinicaltrials.gov·just now
STAT+: Fresh turmoil roils American Diabetes Association following controversy at conference
STAT·1h ago
Brain Implants Are Physically Rewiring Damaged Spines
yesilscience.com·1h ago
Predicting biotech clinical trials & a new Alzheimer’s drug controversy
STAT·2h ago
STAT+: GOP blocks effort to end Medicare test of AI prior authorization
STAT·3h ago
Blood-based gene expression tests show potential for early pancreatic cancer detection
news-medical.net·3h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.